SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing renewed market attention driven by its institutional-grade post-quantum security features and its classification as a digital commodity. While the community remains divided between long-term holders optimistic about its real-world asset tokenization potential and bears focused on historic price performance, active discussions highlight a surge in trading volume and increased social dominance.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing investor attention as community members debate its potential to decouple from Bitcoin and outperform as a peer-to-peer electronic cash system. Discussions are heavily focused on its resilience, upcoming protocol upgrades, and potential for a breakout as participants speculate on it reclaiming its position as a market leader.

U.S. Gold Corp. engages in the exploration of gold properties. It has properties in CK Gold Project, Wyoming, Challis Gold Project, Idaho, and Keystone, Nevada. The company was founded in 1967 and is headquartered in Elko, NV.

U.S. Gold Corp

U.S. Gold Corp ($USAU) is trending as investors focus on its near-term catalysts, including its upcoming inclusion in the Russell index and the highly anticipated completion of a feasibility study for the CK Gold Project. While community members highlight the project's de-risking and potential for institutional inflows, discussions are also dominated by concerns over the high volume of automated accounts pumping the stock.

Norfolk Southern Corp. is a transportation company, which engages in the rail transportation of raw materials, intermediate products, and finished goods. The company also transports overseas freight through several Atlantic and Gulf Coast ports. Its services include property leases and sales, wire line or pipeline and fiber optics projects, access property, managing private crossings, promoting businesses with signboards, and natural resource management. The company was founded on July 23, 1980, and is headquartered in Atlanta, GA.

Norfolk Southern Corp.

Norfolk Southern is trending as investors react to a significant accounting shift involving a multi-million dollar lease renewal in Atlanta, which the company has reclassified as a finance lease. Community discourse is currently split between analyzing the impact of this increased balance sheet leverage on the company's long-term financial health and ongoing discussions regarding operational challenges and broader rail sector sentiment.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is seeing heightened investor attention following a series of clinical wins and regulatory milestones in its oncology and immunology portfolios, including strong performance data for its multiple myeloma franchise. While the community remains focused on these pipeline developments and growth catalysts, discussion is balanced by ongoing monitoring of significant talc-related legal liabilities and potential regulatory impacts on pricing.

Maul Coin

Maul Coin is gaining momentum as community members actively rally to build a long-term foundation, emphasizing transparency and active creator involvement to distinguish the project from typical pump-and-dump schemes. The community is focused on increasing holder count, driving social media engagement, and pushing for official chart verification to fuel organic growth.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is seeing significant community engagement as investors debate its long-term potential following recent integrations and post-quantum security developments. While some participants express frustration over price volatility and token supply concerns, others are actively accumulating the asset, citing the project's institutional partnerships and foundational role in the evolving AI agent sector.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors digest the FDA approval of Foundayo, the company's first oral GLP-1 weight-loss pill, which significantly intensifies the competitive landscape against Novo Nordisk. Community discussion is heavily focused on the clinical efficacy and side-effect profile of Foundayo versus oral Wegovy, while broader sentiment remains polarized between enthusiasm for Lilly's commercial execution and concerns regarding supply chain hurdles and intensifying pricing competition.

Invesco DB US Dollar Index Bullish Fund - Common units of beneficial interest

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund is currently trending as markets weigh escalating trade tensions and geopolitical uncertainty against conflicting labor data and shifting Federal Reserve rate expectations. Investors are actively debating the dollar's role as a safe-haven asset amidst potential policy realignments, currency intervention risks, and ongoing debates over U.S. fiscal deficits and de-dollarization.

Agree Realty Corp. is a real estate investment trust, which engages in the ownership, acquisition, development, and management of retail properties net leased to industry tenants. It focuses on the long-term, fee simple ownership of properties net leased to national and large regional retailers. The company was founded by Richard Agree in 1971 and is headquartered in Royal Oak, MI.

Agree Realty Corp.

Agree Realty (ADC) is trending as investors monitor its resilient performance in the net-lease REIT sector, with the community frequently debating its growth trajectory and dividend quality relative to peers like Realty Income. Discussions are anchored in the firm's strategic management, robust portfolio quality, and recent insider buying activity, which have bolstered investor sentiment during broader market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Following the transaction, Geert R. owns 120,815 shares of the company.&nbsp;</li><li>Cel-Sci is most known for its experimental cancer treatment called Multikine.</li><li>The company is currently preparing to conduct a confirmatory registration study for the treatment which will enroll 212 patients.</li></ul>Shares of CEL-SCI Corp. (CVM) rallied 7% on Monday after its CEO Kersten Geert R. purchased 38,023 shares of restricted stock directly from the Company.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/725363/000123603026000002/xslF345X05/primary_doc.xml">filing</a> with the U.S. Securities and Exchange Commission, Geert made the purchase on Jan. 22 at the closing price on Jan 21 or $5.26 per share.This transaction amounts to about $200,000. Following the transaction, the CEO owns 120,815 shares of the company.<h2 class="st-heading-2">Cel-Sci’s Pipeline</h2>Cel-Sci is known for its experimental cancer treatment, Multikine. It is designed to help the immune system "target" the tumor before surgery, radiation and chemotherapy.The company is currently preparing to conduct a confirmatory registration study for the treatment which will enroll 212 patients with newly diagnosed locally advanced not yet treated resectable head and neck cancer. Enrollment is expected to begin for the trial in spring 2026 and the company intends to seek approval based on data generated by 2028.During the fiscal year ended September, the company reported a net loss of $25.4 million, down from the $27.6 million reported in fiscal 2024.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CVM stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said the stock is one to “watch closely.”<stembedurl>https://www.stocktwits.com/topstockalerts/message/642897665</stembedurl>Another highlighted that Vanguard Group had previously disclosed ownership of the stock. “Big Money has moved in here for a reason,” they said.<stembedurl>https://www.stocktwits.com/itsverified/message/642877607</stembedurl><a href="https://stocktwits.com/symbol/CVM">CVM stock</a> has dropped nearly 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/iova-shares-jump-whats-retail-expecting/cmy76S5R4h0">IOVA Shares Jump 8% — What’s Retail Expecting?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cel-Sci logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why DID CVM Shares Rally Over 7% Today?

According to a filing with the U.S. Securities and Exchange Commission, CEO Kersten Geert R. purchased 38,023 shares in the company on Jan. 22 at $5.26 per share.

Equity

According to a filing with the U.S. Securities and Exchange Commission, CEO Kersten Geert R. purchased 38,023 shares in the company on Jan. 22 at $5.26 per share.


Retail chatter picked up on Cel-Sci Corporation on Wednesday as investors awaited a key decision from the Saudi Food and Drug Authority (SFDA) on the company’s application for Breakthrough Medicine Designation for its cancer immunotherapy, Multikine.&nbsp;The ruling could come soon, as the SFDA’s 60-day review window is nearing its close.In August, Cel-Sci signed a Memorandum of Understanding with a leading Saudi pharmaceutical company, which submitted the application to the SFDA. A final commercialization agreement between the two partners is expected in the third quarter of 2025. The Saudi partner is also expected to facilitate reimbursement and accelerate Multikine’s sale and patient access in the Kingdom.The move has drawn growing interest from Saudi investment funds looking to back Multikine and Cel-Sci’s expansion across the Middle East and North Africa region.Multikine is designed to strengthen a patient’s immune system before surgery for newly diagnosed, untreated head and neck cancer. In a global Phase 3 study, the largest of its kind, the therapy improved five-year survival rates to 73% from 45% among patients receiving standard care alone, cutting the risk of death by half.If approved, Multikine would qualify for accelerated patient access and reimbursement under Saudi Arabia’s Breakthrough Medicine Program, which aims to fast-track treatments for serious or life-threatening diseases that meet unmet medical needs.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘high’ message volume.One user noted that Cel-Sci’s April update indicated the company was encouraged to seek conditional approval under the Breakthrough Therapy Designation. The filing was made around mid-August, suggesting a decision could be imminent.<stembedurl>https://stocktwits.com/NavyPatrol657/message/632324726</stembedurl>Another user expressed anticipation for an update from CEO Geert Kersten, while a third observed that the stock might remain subdued until the SFDA announcement.<stembedurl>https://stocktwits.com/prophet777/message/632356422</stembedurl><stembedurl>https://stocktwits.com/NoobFriendly/message/632216212</stembedurl><a href="https://stocktwits.com/symbol/CVM">CEL-SCI Corporation’s stock</a> has declined 18% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEL-SCI Corporation’s stock (CVM) has declined 18% so far in 2025.| Image source: Getty Images

Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine

Multikine is a cancer immunotherapy, which has significantly improved survival in head and neck cancer patients during global Phase 3 trials.

CEL-SCI Corporation (CVM) on Friday announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical companies for a partnership that spans regulatory and commercial activities for Multikine in the Kingdom of Saudi Arabia.<a href="https://stocktwits.com/symbol/CVM">CEL-SCI</a>’s shares were trading 33% higher at the time of writing.The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250711051288/en/CEL-SCI-to-Sign-Partnership-Agreement-With-Leading-Saudi-Arabian-Pharma-Company-for-Multikine-in-the-Treatment-of-Head-Neck-Cancer">said</a>. The partner will then file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA).Multikine is a cancer drug administered before surgery as a treatment for newly diagnosed and previously untreated head and neck cancer.If granted Breakthrough Medicine Designation, Multikine would immediately become available for patient access, reimbursement, or sale in Saudi Arabia. CEL-SCI said that it believes Multikine meets all requirements for Breakthrough Medicine Designation as published by the SFDA and is now developing a comprehensive commercialization plan with its Saudi pharma partner.In a study spanning 20 countries, Multikine increased the 5-year survival rate of the target patient population to 73% versus 45% in patients treated with standard of care alone. The 5-year risk of death was halved from 55% to 27%.The drug, given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.CEL-SCI also said on Friday that several Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.On Stocktwits, retail sentiment around CVM jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_11_59_25_AM_png_2f84b0779d.webp" alt="CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>CVM stock is down by 58% this year and by over 86% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-reportedly-stands-firm-on-eu-ad-model/ch8cirOR5Zw">Meta Reportedly Stands Firm On EU Ad Model Amid Looming Regulatory Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled

The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, CEL-SCI said.

Shares of Cel-Sci Corp ($CVM) slipped in the after-hours trading session on Friday following the company’s announcement of a share offering, with retail sentiment staying neutral. The purchase price of the offering, for its common stock par value of $0.01 per share, wasn’t immediately known. The last reported sale price of its stock was $0.70 per share. According to the company’s filing with the SEC, it is offering potential purchasers, along with related parties who own more than 4.99% of its outstanding common stock immediately following the consummation of this offering, the opportunity to purchase pre-funded warrants exercisable at an exercise price of $0.01 per share.The purchase price of each pre-funded warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01, the statement said.The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full, the statement added. For each warrant, the number of shares of common stock on offer will be decreased on a one-for-one basis.&nbsp; Retail sentiment on Stocktwits has been ‘neutral’ compared to a week ago. Message volumes have been in the normal range. &nbsp;<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_at_11_21_09_AM_2d60d70bed.png" alt="Screenshot 2024-12-30 at 11.21.09 AM.png" width="1256" height="302"><figcaption>CVM sentiment meter and message volumes on Dec 29</figcaption></figure><stembedurl>https://stocktwits.com/phoenix31415/message/598120019</stembedurl>A ‘bearish’ commenter was not convinced on the terms.<stembedurl>https://stocktwits.com/ThaDreadPirate/message/598079934</stembedurl>The company has engaged ThinkEquity as the placement agent in connection with this offering.Cel-Sci develops immunotherapy products for the treatment of cancer and infectious diseases.Cel-Sci stock is down 77% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cel-Sci Stock Slips After Public Offering: Retail's Neutral

The purchase price of each pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

CVM
Cel-Sci Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CVM News

CVMCel-Sci Corp